Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Laking, G. R.
Right arrow Articles by Price, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laking, G. R.
Right arrow Articles by Price, P. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:345-347, 2002
© 2002 European Society for Medical Oncology

Editorial

FDG-PET for response assessment: answers in search of questions

G. R. Laking1 and P. M. Price2

1The CRC PET Oncology Group, Hammersmith Hospital, London 2Christie Hospital, Manchester, UK

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) exploits the abnormal energy metabolism of tumours to enable ‘functional’ as opposed to ‘structural’ imaging. The last decade has seen more than 100 reports of the sensitivity and specificity of FDG-PET for the detection and staging of cancer in various settings [1]. These show that a combination of PET and conventional imaging mostly outperforms conventional imaging on its own, in its ability to predict histopathological reference findings. The progression of research in clinical PET to address combined modality therapies is welcome, and it is encouraging to see the results of groups represented by Flamen and colleagues published in dedicated oncological journals such as the Annals [2]. The increasing predictive power of diagnostic technologies is bound to change the way we practice medicine in coming years. In fact, the technologies themselves are already here; the real challenge is to identify . . . [Full Text of this Article]

Acknowledgements

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?